Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) FCF Margin (2025)

Updated

Evommune's FCF Margin came in at -589.82% for FY2025, up 242.80 percentage points from -832.61% in FY2024.

Analysis

Evommune (EVMN) FCF Margin (2025) Analysis & Trends

  • Per Business Quant, earlier years put FCF Margin at -832.61% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 33.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 25.03%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 41.97%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.51%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 52.85%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.25%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 57.81%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 28.96%
10 Evommune 285.17 Mn -352.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -97.66%
Mar 31, 2025 -796.63%
API Access

Evommune FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=EVMN&period=max&api_key=YOUR_API_KEY